Can drugs or micronutrients prevent cataract?

Drugs and Aging

Volumn 18, Issue 7, 2001, Pages 473-486

  Harding, J J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; ALPHA TOCOPHEROL; AMINOGUANIDINE; ASCORBIC ACID; BETA CAROTENE; CALPASTATIN; EPALRESTAT; ESTROGEN; EYE DROPS; FLURBIPROFEN; GLUTATHIONE; IBUPROFEN; IMIRESTAT; NAPROXEN; PANTETHINE; PARACETAMOL; PONALRESTAT; PYRUVIC ACID; RETINOL; SORBINIL; SORBITOL; SULINDAC; TOLRESTAT; TRACE ELEMENT; XANTHOPHYLL;

ANTIOXIDANT ACTIVITY; CATARACT; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; GLYCATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VITAMIN INTAKE;

EID: 0034918751     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118070-00001     Document Type: Review

References (131)

1. The content and cost of cataract surgery
2. The deficit in cataract surgery in England and Wales and the escalating problem of visual impairment: Epidemiological modelling of the population dynamics of cataract
3. Pharmacological treatment strategies in age-related cataracts
4. Nutrition supplements and the eye
5. Cataract in Punjab
6. Age-related nuclear lens opacities are associated with reduced growth before 1 year of age
7. Scientific basis for medical therapy of cataracts by antioxidants
8. Nutrition and eye disease of the elderly
9. Modelling cortical cataractogenesis XI: Vitamin C reduces g-crystallin leakage from lenses of diabetic rats
10. Effect of age and diet on development of cataract in the diabetic rat
11. Inhibition of steroid-induced cataract in rat eyes by administration of vitamin-E ophthalmic solution
12. Effect of vitamin E eye drops on naphthalene-induced cataract in rats
13. Preventive effect of topical vitamin-E containing liposome instillation on the progression of galactose cataract: Comparison between 5-week and 12-week old rats fed a 25% galactose diet
14. The Emory mouse cataract: The effects on cataractogenesis of α-tocopherol, penicillamine, triethylene-tetramine, and mercaptopropionylglycine
15. Relationship in humans between ascorbic acid consumption and levels of total and reduced ascorbic acid in lens, aqueous humour, and plasma
16. India-US case-control study of age-related cataracts
17. Risk factors for age-related cortical, nuclear and posterior subcapsular cataracts
18. Antioxidant vitamins and nuclear opacities
19. Vitamin E intake and risk of cataract in humans
20. The lens opacities case-control study: Risk factors for cataract
21. Relation between lens opacities and vitamin and mineral supplement use
22. Nutrient intake and cataract extraction in women: A prospective study
23. The use of vitamin supplements and the risk of cataract among US male physicians
24. The Linxian cataract studies: Two nutrition intervention trials
25. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study
26. Food and nutrient intake and risk of cataract
27. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women
28. A prospective study of vitamin supplement intake and cataract extraction among US women
29. Incidence of cataract operations in Finnish male smokers unaffected by α-tocopherol or β-carotene supplements
30. A prospective study of carotenoid intake and risk of cataract extraction in US men
31. The REACT trial: Antioxidant micronutrient mixture to slow progression of age-related cataract
32. Senile cataracts: Evidence for acceleration by diabetes and deceleration by salicylates
33. Aspirin and senile cataracts in rheumatoid arthritis
34. Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro: A possible mechanism by which aspirin could prevent cataract
35. Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: In vitro and in vivo studies
36. Aspirin prevents the nonenzymic glycosylation and carbamylation of the human eye crystallins in vitro
37. Non-enzymic glycosylation (glycation) of lens proteins by galactose and protection by aspirin and reduced glutathione
38. Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo
39. The non-enzymic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione
40. Reaction of aspirin with cysteinyl residues of lens γ-crystallins: A mechanism for the proposed anti-cataract effect of aspirin
41. In vivo acetylation identified at lysine 70 of human lens αA-crystallin
42. Non-enzymic modification of lens proteins by glucose and fructose, and effects of ibuprofen
43. Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose
44. Aspirin in experimental cataractogenesis
45. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen
46. Relationship between aldose reductase inhibiting activity and anti-cataract action of various nonsteroidal anti-inflammatory drugs
47. The role of prostaglandins E2 and F2 alpha in ultraviolet radiation-induced cortical cataracts in vivo
48. Effects of some probable anti-oxidants on selenite-induced cataract formation and oxidative stress-related parameters in rats
49. Do aspirin-like analgesics protect against cataract? A case control study
50. Drugs including alcohol that act as risk factors for cataract, and possible protection against cataract by aspirin-like analgesics and cyclopenthiazide
51. Protection against cataract by aspirin, paracetamol and ibuprofen
52. Case-control study of cataract in Oxford
53. Lack of evidence for aspirin use and prevention of cataracts
54. Low dose aspirin and risk of cataract in a randomised trial of US physicians
55. Final report on the aspirin component of the ongoing Physicians' Health Study
56. Aspirin effects on the development of cataracts in patients with diabetes mellitus
57. A prospective study of aspirin use and cataract extraction in women
58. Low-dose aspirin and risk of cataract and subtypes in a randomised trial of US physicians
59. Medications and cataract
60. Aspirin and cataract
61. Secondary prevention of vascular disease by prolonged antiplatelet treatment
62. Aspirin in the prevention of strokes
63. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists
64. Chemoprevention of colorectal cancer
65. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study
66. Alzheimer disease (AD), modified proteins, and aspirin
67. Alzheimer disease and cataract: Common threads
68. Formation of polyols by the lens of the rat with sugar cataract
69. Osmotic changes in experimental galactose cataract
70. Aldose reductase: A window to the treatment of diabetic complications?
71. An unlikely sugar substrate site in the 1.65A structure of the human aldose reductase holoenzyme implicated in diabetic complications
72. 31P nuclear magnetic resonance spectroscopy in the study of the sorbitol pathway and aldose reductase inhibition in intact rabbit lenses
73. Vitamin C: An aldose reductase inhibitor that normalises erythrocyte sorbitol in insulin-dependent diabetes-mellitus
74. Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract
75. Effects of a new aldose reductase inhibitor on diabetic complications in rats
76. Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus
77. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats
78. Efficacy of AL01576 in preventing naphthalene cataract in three rat strains: A slit lamp and Sceimpflug photographic study
79. Effect of aldose reductase inhibitors on naphthalene cataract formation in the rat
80. Inhibition of naphthalene cataract in rats by aldose reductase inhibitors
81. Aldose reductase in glucose toxicity: A potential target for the prevention of diabetic complications
82. Clinical trials with aldose reductase inhibitors
83. Current progress in clinical trials of aldose reductase inhibitors in Japan
84. Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches
85. Epalrestat, an aldose reductase inhibitor, reduces the levels of N-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients
86. Free and protein-bound glutathione in normal and cataractous lenses
87. Kontrollierte klinische studie uber die wirksankeit von phakan als antikataractmedicament
88. Glutathione inhibits the glycation and crosslinking of lens proteins by ascorbic acid
89. Augmentation of human and rat lenticular glutathione in vitro by prodrugs of gamma-glutamyl-cysteine
90. Glutathione ester prevents buthionine sulfoximine-induced cataracts and lens epithelial cell damage
91. Anticataractogenic property of γ-glutamylcysteine ethyl ester in an animal model of cataract
92. Effect of selected anti-cataract agents on opacification in the selenite cataract model
93. The lens: Metabolism and cataract
94. Glutathione isopropyl ester (YM737) inhibits the progression of X-ray-induced cataract
95. Prevention of acetaminophen- and naphthalene-induced cataract and glutathione loss by CySSMe
96. Prevention of naphthalene-induced cataract and hepatic glutathione loss by the cysteine prodrugs, MTCA and PTCA
97. Effects of 2-mercaptopropionylglycine on the development of X-ray-induced cataract in rats
98. Preventive effect of SA3443, a novel cyclic disulfide, on glucocorticoid-induced cataract formation of developing chick embryo
99. Evaluation of AL-05712 and AL-05741 as thioltransferase mimics for the prevention and recovery of pre-cataractous changes in lens
100. The prevention of cataract caused by oxidative stress in cultured rat lenses. I. H202 and photochemically-induced cataract
101. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
102. Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymic glycosylation
103. The effects of aminoguanidine on the glycation (nonenzymic glycosylation) of lens proteins
104. Inhibition of cataracts in moderately diabetic rats by aminoguanidine
105. Cysteine protease inhibitor E64 reduces the rate of formation of selenite cataract in the whole animal
106. Amelioration of cataracts and proteolysis in cultured lenses by cysteine protease inhibitor E64
107. Role of calpain in hydrogen peroxide induced cataract
108. Superior prevention of calcium ionophore cataract by E64d
109. Calcium ionophore induced proteolysis and cataract: Inhibition by cell-permeable calpain antagonists
110. SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: Amelioration of cataract in cultured rat lenses
111. Modelling cortical cataractogenesis XXIX: Calpain proteolysis of lens fodrin in cataract
112. Is there evidence of an estrogen effect on age-related lens opacities?
113. Estrogens and cataract
114. Effects of estrogen use on lens transmittance in postmenopausal women
115. Hormone replacement therapy, reproductive factors, and cataract: The Blue Mountains eye study
116. Protective effects of estrogen in a rat model of age-related cataracts
117. Estrogen protects lenses against cataract by transforming growth factor β (TGFβ)
118. Lens opacification by anti-oestrogens: Tamoxifen vs ICI 182,780
119. Theoretical and experimental basis for the inhibition of cataract
120. Inhibition of lens opacification during the early stages of cataract formation
121. Loss of cytoskeletal proteins and lens cell opacifiication in the selenite cataract model
122. Delay or inhibition of rat lens opacification using pantethine or WR-77913
123. Pantethine inhibits the formation of high-Tc protein aggregates in gammaB-crystallin solutions
124. Small heat-shock proteins and their potential role in human disease
125. Prevention of oxidative damage to rat lens by pyruvate in vitro: Possible attenuation in vivo
126. Attenuation of sugar cataract by ethyl pyruvate
127. Molecular chaperones protect against glycation-induced inactivation of glucose 6-phosphate dehydrogenase
128. Fructose induced deactivation of glucose 6-phosphate dehydrogenase activity and its prevention by pyruvate: Implications in cataract prevention
129. Fructose mediated damage to lens alpha-crystallin: Prevention by pyruvate